POG 8625

A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA 1 Hodgkin disease: A report from the children's oncology group

Faith H. Kung, Cindy L. Schwartz, Carolyn R. Ferree, Wendy B. London, Jessie L. Ternberg, Fred G. Behm, Moody D. Wharam, John M. Falletta, Pedro De Alarcon, Allen R. Chauvenet

Research output: Contribution to journalArticle

Abstract

To determine if 6 courses of chemotherapy alone could achieve the same or better outcome than 4 courses of chemotherapy followed by radiation therapy (chemoradiotherapy) in pediatric and adolescent patients with Hodgkin disease. Children ≤21 years old with biopsy-proven, pathologically staged I, IIA, or IIIA 1 Hodgkin disease were randomly assigned 6 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine (treatment 1) or 4 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine +2550 cGy involved-field radiotherapy (treatment 2). The complete response rate was 89%, with a complete response and partial response rate of 99.4%. There was no statistically significant difference in event-free survival (EFS) or overall survival between arms. The EFS for those who achieved an early complete response was significantly higher than for those who did not. For pediatric patients with asymptomatic low-stage and intermediate-stage Hodgkin disease, chemotherapy and chemoradiotherapy both resulted in 3-year EFS of approximately 90% and statistically indistinguishable 8-year EFS and overall survival, without significant long-term toxicity. Early response to therapy was associated with higher EFS, a concept that has led to the Children's Oncology Group paradigm of response-based risk-adapted therapy for pediatric Hodgkin disease.

Original languageEnglish (US)
Pages (from-to)362-368
Number of pages7
JournalJournal of Pediatric Hematology/Oncology
Volume28
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Hodgkin Disease
Disease-Free Survival
Radiotherapy
Drug Therapy
Procarbazine
Mechlorethamine
Dacarbazine
Vinblastine
Bleomycin
Vincristine
Pediatrics
Prednisone
Doxorubicin
Survival
Therapeutics
Biopsy

Keywords

  • Chemotherapy versus chemoradiotherapy
  • Children
  • Hodgkin disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

POG 8625 : A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA 1 Hodgkin disease: A report from the children's oncology group. / Kung, Faith H.; Schwartz, Cindy L.; Ferree, Carolyn R.; London, Wendy B.; Ternberg, Jessie L.; Behm, Fred G.; Wharam, Moody D.; Falletta, John M.; De Alarcon, Pedro; Chauvenet, Allen R.

In: Journal of Pediatric Hematology/Oncology, Vol. 28, No. 6, 06.2006, p. 362-368.

Research output: Contribution to journalArticle

Kung, Faith H. ; Schwartz, Cindy L. ; Ferree, Carolyn R. ; London, Wendy B. ; Ternberg, Jessie L. ; Behm, Fred G. ; Wharam, Moody D. ; Falletta, John M. ; De Alarcon, Pedro ; Chauvenet, Allen R. / POG 8625 : A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA 1 Hodgkin disease: A report from the children's oncology group. In: Journal of Pediatric Hematology/Oncology. 2006 ; Vol. 28, No. 6. pp. 362-368.
@article{ce63639fadc54997af4fe4e028e8373c,
title = "POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA 1 Hodgkin disease: A report from the children's oncology group",
abstract = "To determine if 6 courses of chemotherapy alone could achieve the same or better outcome than 4 courses of chemotherapy followed by radiation therapy (chemoradiotherapy) in pediatric and adolescent patients with Hodgkin disease. Children ≤21 years old with biopsy-proven, pathologically staged I, IIA, or IIIA 1 Hodgkin disease were randomly assigned 6 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine (treatment 1) or 4 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine +2550 cGy involved-field radiotherapy (treatment 2). The complete response rate was 89{\%}, with a complete response and partial response rate of 99.4{\%}. There was no statistically significant difference in event-free survival (EFS) or overall survival between arms. The EFS for those who achieved an early complete response was significantly higher than for those who did not. For pediatric patients with asymptomatic low-stage and intermediate-stage Hodgkin disease, chemotherapy and chemoradiotherapy both resulted in 3-year EFS of approximately 90{\%} and statistically indistinguishable 8-year EFS and overall survival, without significant long-term toxicity. Early response to therapy was associated with higher EFS, a concept that has led to the Children's Oncology Group paradigm of response-based risk-adapted therapy for pediatric Hodgkin disease.",
keywords = "Chemotherapy versus chemoradiotherapy, Children, Hodgkin disease",
author = "Kung, {Faith H.} and Schwartz, {Cindy L.} and Ferree, {Carolyn R.} and London, {Wendy B.} and Ternberg, {Jessie L.} and Behm, {Fred G.} and Wharam, {Moody D.} and Falletta, {John M.} and {De Alarcon}, Pedro and Chauvenet, {Allen R.}",
year = "2006",
month = "6",
doi = "10.1097/00043426-200606000-00008",
language = "English (US)",
volume = "28",
pages = "362--368",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - POG 8625

T2 - A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA 1 Hodgkin disease: A report from the children's oncology group

AU - Kung, Faith H.

AU - Schwartz, Cindy L.

AU - Ferree, Carolyn R.

AU - London, Wendy B.

AU - Ternberg, Jessie L.

AU - Behm, Fred G.

AU - Wharam, Moody D.

AU - Falletta, John M.

AU - De Alarcon, Pedro

AU - Chauvenet, Allen R.

PY - 2006/6

Y1 - 2006/6

N2 - To determine if 6 courses of chemotherapy alone could achieve the same or better outcome than 4 courses of chemotherapy followed by radiation therapy (chemoradiotherapy) in pediatric and adolescent patients with Hodgkin disease. Children ≤21 years old with biopsy-proven, pathologically staged I, IIA, or IIIA 1 Hodgkin disease were randomly assigned 6 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine (treatment 1) or 4 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine +2550 cGy involved-field radiotherapy (treatment 2). The complete response rate was 89%, with a complete response and partial response rate of 99.4%. There was no statistically significant difference in event-free survival (EFS) or overall survival between arms. The EFS for those who achieved an early complete response was significantly higher than for those who did not. For pediatric patients with asymptomatic low-stage and intermediate-stage Hodgkin disease, chemotherapy and chemoradiotherapy both resulted in 3-year EFS of approximately 90% and statistically indistinguishable 8-year EFS and overall survival, without significant long-term toxicity. Early response to therapy was associated with higher EFS, a concept that has led to the Children's Oncology Group paradigm of response-based risk-adapted therapy for pediatric Hodgkin disease.

AB - To determine if 6 courses of chemotherapy alone could achieve the same or better outcome than 4 courses of chemotherapy followed by radiation therapy (chemoradiotherapy) in pediatric and adolescent patients with Hodgkin disease. Children ≤21 years old with biopsy-proven, pathologically staged I, IIA, or IIIA 1 Hodgkin disease were randomly assigned 6 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine (treatment 1) or 4 courses of alternating nitrogen mustard, oncovin, prednisone, and procarbazine/doxorubicin, bleomycin, vinblastine, and dacarbazine +2550 cGy involved-field radiotherapy (treatment 2). The complete response rate was 89%, with a complete response and partial response rate of 99.4%. There was no statistically significant difference in event-free survival (EFS) or overall survival between arms. The EFS for those who achieved an early complete response was significantly higher than for those who did not. For pediatric patients with asymptomatic low-stage and intermediate-stage Hodgkin disease, chemotherapy and chemoradiotherapy both resulted in 3-year EFS of approximately 90% and statistically indistinguishable 8-year EFS and overall survival, without significant long-term toxicity. Early response to therapy was associated with higher EFS, a concept that has led to the Children's Oncology Group paradigm of response-based risk-adapted therapy for pediatric Hodgkin disease.

KW - Chemotherapy versus chemoradiotherapy

KW - Children

KW - Hodgkin disease

UR - http://www.scopus.com/inward/record.url?scp=33745677279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745677279&partnerID=8YFLogxK

U2 - 10.1097/00043426-200606000-00008

DO - 10.1097/00043426-200606000-00008

M3 - Article

VL - 28

SP - 362

EP - 368

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 6

ER -